MOSCOW – The Siberian Institute of Vector Virology on Tuesday completed the first human trials, known as Phase II, of a Russian vaccine currently opposed to COVID-19, the state-owned news firm Interfax reported.
Russia registered its first candidate vaccine, developed through the Gamaleya Institute in Moscow, in August after completing the first human trials.
“Today . . . The last of the 20 volunteers has been discharged from the hospital,” guard dog Rospotrebnadzor said in a statement.
“All one hundred volunteers were vaccinated with two doses and underwent a 23-day follow-up era in the hospital. The volunteers are feeling fine. (Report via Maria Kannedova; Written via Polina Ivanova Edited via Gareth Jones)
Sign up for news from the National Post, a department of Postmedia Network Inc.
An error has occurred, provide a valid email address.
A welcome email is on the way. If you don’t see it, check your junk folder.
The next factor in the newsletter will soon be in your inbox.
We found a challenge when you signed up. Check again
Postmedia is committed to maintaining an even civil discussion forum and encouraging all readers to express their opinions as a percentage of our articles. Comments can take up to an hour to moderate before appearing on the site. We ask that you keep your comments applicable and respectful. I’ve enabled email notifications. You will now receive an email if you get a reaction to your comment, an update to a comment thread that follows, or if a user follows it. See our network regulations for more data and key points on how to adjust your email settings.
365 Bloor Street East, Toronto, Ontario, M4W 3L4
© 2020 National Post, a department of Postmedia Network Inc. All rights reserved. Unauthorized broadcasting, transmission or transmission is strictly prohibited.
This uses cookies to personalize your content (including ads) and allows us to analyze our traffic. Learn more about cookies here. By using our site, you agree to our terms of use and our privacy policy.